Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (6087)	4/4/2002 2:17:28 PM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

Tuck: Do you know if CIPH's SELDI P.Chip will be used to detect osteopontin or if they have another "marker" for detection of ovarian Ca ? I read with interest the article on JAMA.2002;287:1671-1679 Dr.S.C.Mok, the senior author, is from Boston's Brigham & Women's Hospital. The ELISA kits that were used reportedly were supplied by Immuno-Biological Labs. which I understand has applied for a patent for osteopontin detection kits. They stated that there are a variety of arbitrary choices for reporting specificity and sensitivity estimates and with their choice of reporting.<g> their specificity result was 80%. That was less than the 96% on the article you mentioned in which the study apparently was done by Northwestern ? RAGL Bernard

To: tuck who wrote (6087)	4/16/2002 5:24:18 PM
From: Archie Meeties	Read Replies (2) \| Respond to of 52153

The only comment to offer is that sensitivity and specificity are not the data you should be interested in. What you want to know is if early detection by seldi in those various cancers is early enough to influence treatment or change morbitidy/mortality. Even if the sensitivity was lower, if there was a remarkable diffrence in outcomes by early detection, the technology would be used. Because they didn't say otherwise, you have to assume that the numbers you see are in patients already diagnosed with the various cancers. That's nothing to get excited about. If, on the otherhand, these patients had occult disease which was diagnosed by seldi prior to the usual clinical/radiographic diagnosis, that would be interesting (next step). It still wouldn't be useful unless early diagnosis could influence treatment (for example, diagnosis prior to metastases).